Boston Scientific (BSX) Change in Accured Expenses (2020 - 2026)

Boston Scientific has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$512.0 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$512.0 million, down 32.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $169.0 million (down 45.13% YoY), and the FY2025 annual result was $296.0 million, up 21.81% from the prior year.
• Change in Accured Expenses came in at -$512.0 million for Q1 2026 at Boston Scientific, down from $285.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $385.0 million in Q4 2024 to a low of -$512.0 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $23.0 million (2023), against an average of -$6.5 million.
• Across the five-year window, Change in Accured Expenses slumped 5357.14% in 2022 and soared 1573.91% in 2024, its largest moves.
• Boston Scientific's Change in Accured Expenses stood at $335.0 million in 2022, then tumbled by 93.13% to $23.0 million in 2023, then jumped by 1573.91% to $385.0 million in 2024, then retreated by 25.97% to $285.0 million in 2025, then tumbled by 279.65% to -$512.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$512.0 million (Q1 2026), $285.0 million (Q4 2025), and $165.0 million (Q3 2025), per Business Quant data.